Type 5 Cyclic Nucleotide Phosphodiesterases

A cyclic nucleotide phosphodiesterase subfamily that is highly specific for CYCLIC GMP. It is found predominantly in vascular tissue and plays an important role in regulating VASCULAR SMOOTH MUSCLE contraction.

Also Known As:

Cyclic Nucleotide Phosphodiesterases, Type 5; PDE5 Phosphodiesterases; Phosphodiesterase 5; Phosphodiesterase 5A; Phosphodiesterase 5A, cGMP-Specific; Phosphodiesterase Type 5; Phosphodiesterase Type V; Phosphodiesterase V; Phosphodiesterase-5; cGMP-Binding, cGMP-Specific 3',5'-cyclic Nucleotide Phosphodiesterase; Phosphodiesterase 5A, cGMP Specific; Phosphodiesterases, PDE5; Type 5, Phosphodiesterase; Type V, Phosphodiesterase; cGMP-Specific Phosphodiesterase 5A

Networked: 1544 relevant articles (174 outcomes, 219 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kukreja, Rakesh C: 26 articles (11/2020 - 01/2005)
2.	Kloner, Robert A: 18 articles (10/2021 - 07/2003)
3.	Burnett, Arthur L: 17 articles (01/2022 - 07/2004)
4.	Das, Anindita: 14 articles (11/2020 - 04/2005)
5.	Salloum, Fadi N: 13 articles (10/2021 - 03/2006)
6.	Redfield, Margaret M: 13 articles (01/2021 - 03/2013)
7.	Suh, Jun-Kyu: 13 articles (01/2020 - 04/2008)
8.	Kass, David A: 11 articles (01/2022 - 02/2005)
9.	Xi, Lei: 11 articles (11/2020 - 04/2005)
10.	Ryu, Ji-Kan: 11 articles (01/2020 - 03/2011)

Related Diseases

1.	Erectile Dysfunction 07/02/2019 - "Even if oral type 5 phosphodiesterase inhibitors (PDE5i) seem an effective treatment for erectile dysfunction (ED), the drop-out is high among patients. " 08/01/2018 - " with phosphodiesterase-5 inhibitors, which are well established in the treatment of erectile dysfunction (ED) gives significant improvement in LUTS and post-void residual and can therefore be recommended for patients with LUTS and ED.Phytotherapies" 02/01/2013 - "Phosphodiesterase type 5 (PDE-5) inhibitors are effective for the treatment of erectile dysfunction (ED), and large-scale epidemiologic studies suggest a strong link between LUTS and ED. " 12/01/2006 - "The advent of oral phosphodiesterase type 5 (PDE-5) inhibitors, however, has greatly enhanced erectile dysfunction treatment; patients have demonstrated high tolerability and success rates for improved erectile function. " 01/01/2020 - "Type V-phosphodiesterase-inhibitors (PDE5i) are the first choice drugs in the treatment of erectile dysfunction (ED), being effective in 60-70% of patients. "
2.	Pulmonary Arterial Hypertension 09/01/2017 - "Phosphodiesterase-5 inhibitors (PDE5i) have been shown to be beneficial for patients with pulmonary arterial hypertension. " 01/01/2019 - "Phosphodiesterase-5 inhibitors (PDE-5I) have demonstrated improvement in disease symptoms and quality of life for patients with pulmonary arterial hypertension (PAH). " 07/01/2020 - "The study included 106 incident patients from the Swedish Pulmonary Arterial Hypertension Registry, treated with phosphodiesterase-5 inhibitors for ≥90 days, who were not at a pre-specified treatment goal, i.e. " 08/01/2005 - "This study explored phosphodiesterase type 5 (PDE5) inhibition as a strategy for treating high altitude pulmonary arterial hypertension (HAPH). " 09/15/2023 - "Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry."
3.	Heart Failure 01/01/2022 - "The mitochondrial regulator PGC1α is induced by cGMP-PKG signaling and mediates the protective effects of phosphodiesterase 5 inhibition in heart failure." 01/01/2003 - "Further studies are warranted to characterize the safety and efficacy of type 5 phosphodiesterase inhibition in the treatment of chronic heart failure." 07/12/2011 - "The multifaceted response to phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction includes improvement in pulmonary pressure and vasomotility, RV function and dimension, left ventricular relaxation and distensibility (structural changes and/or ventricular interdependence), and lung interstitial water metabolism (wedge pulmonary pressure decrease improving hydrostatic balance and right atrial pressure reduction facilitating lung lymphatic drainage). " 05/01/2021 - "This is a post-hoc analysis of the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) trial. " 03/01/2020 - "The Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) trial enrolled a high proportion of CKD participants, allowing investigation into differences in HFpEF by CKD status. "
4.	Pulmonary Hypertension 05/01/2009 - "cGMP-specific phosphodiesterase 5 (PDE5) inhibition has been shown to be effective in improving pulmonary haemodynamics in both animal models and clinic patients with pulmonary hypertension. " 01/01/2018 - "Resting CBF velocity was unaffected by phosphodiesterase-5 inhibitors, but cerebrovascular regulation was improved in ED, pulmonary hypertension, diabetes, Becker's and a group of healthy volunteers. " 01/01/2023 - "Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials." 07/01/2014 - "This study aimed to evaluate the therapeutic benefit of phosphodiesterase-5 (PDE-5) inhibitors in pulmonary hypertension secondary to ILD. " 04/01/2014 - "Recent clinical studies showed the beneficial effects of phosphodiesterase type 5 (PDE-5) inhibitors on the treatment of pulmonary hypertension. "
5.	Reperfusion Injury 10/01/2009 - "The observed protective effects imply that phosphodiesterase-5 inhibition could be a novel therapeutic option in the protection against ischaemia-reperfusion injury in cardiac surgery." 03/01/2013 - "The cardiac and renal protective effects of phosphodiesterase-5 (PDE-5) inhibitors against ischemia-reperfusion injury have recently been demonstrated in animal studies. " 01/01/2014 - "Therefore, phosphodiesterase-5 can be explored as an important target to contain ischemia-reperfusion injury." 02/01/2012 - "Phosphodiesterase-5 inhibitor and rat lung ischemia-reperfusion injury." 01/01/2018 - "Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure."

Related Drugs and Biologics

1.	Phosphodiesterase 5 Inhibitors
2.	Sildenafil Citrate (Viagra)
3.	Tadalafil (Cialis)
4.	Vardenafil Dihydrochloride (Levitra)
5.	Endothelin Receptor Antagonists
6.	Guanosine Monophosphate (5' Guanylic Acid)
7.	Prostaglandins
8.	Nitric Oxide (Nitrogen Monoxide)
9.	riociguat
10.	Soluble Guanylyl Cyclase

Related Therapies and Procedures

1.	Therapeutics
2.	Prostatectomy (Retropubic Prostatectomy)
3.	Radiotherapy
4.	Cardiopulmonary Bypass (Heart-Lung Bypass)
5.	Drug Therapy (Chemotherapy)